01Assess
Begin with the diagnosis
Similar-looking patterns may have different causes and require different next steps.
Clinical Hair Treatments · Istanbul
Diagnosis before method · follow-up before claims
Clinical Hair Treatments
Eleven clinical approaches may serve different purposes. Selection therefore starts with the cause and pattern of hair loss, the scalp findings and a goal that can be reviewed over time — not with a product name.
Photographs may help organise an initial discussion. Diagnosis, product review and the treatment plan require an in-person medical assessment.
Purpose and Scope
Four possible roles
Clinical methods are a distinct route of care, not a label for everything non-surgical.
The category separates clinical purpose, source material, treatment depth and evidence so that each method's task and limits remain clear.
02Support
Consider existing hair
Density, miniaturisation, scalp condition and course guide whether an adjunctive method is reasonable to assess.
03Combine
Give each element a role
A combination is useful only when the purpose, sequence and review point for every element are explicit.
04Observe
Treatment is not automatic
When the cause or benefit-risk balance is unclear, documented observation may be the sounder first step.
Medical Assessment
From pattern to a personal decision
Five levels come before any method decision.
An online review can help organise information. A reliable decision requires an in-person examination and review of the specific procedure or product.
- 01
History and course
Onset, pace, family history, health conditions, medicines and previous treatments are reviewed.
- 02
Pattern and scalp
Distribution, miniaturisation, inflammation, scarring and hair quality are assessed, with trichoscopy when appropriate.
- 03
Treatable cause
Signs of an underlying disorder are investigated before an elective method is selected.
- 04
Method and product
Source, preparation, ingredients, sterility, treatment depth and regulatory setting are considered.
- 05
Aim and review
A measurable aim, timescale and criteria for continuing or stopping are agreed in advance.
Clinical Methods · 01—04
Autologous concentrates · injection · microtissue
Four approaches with different source materials.
Blood products, injected products and autologous tissue are considered separately by preparation, purpose and evidence.
01Autologous blood product
PRP
Platelet-rich plasma is considered in relation to diagnosis, preparation protocol and a defined treatment aim.
Decision boundaryConcentration, preparation and follow-up must be specified.
Open PRP02Fibrin-based blood product
PRF and Autologous Platelet Concentrates
Fibrin-based concentrates are assessed as a separate approach rather than a renamed form of PRP.
Decision boundaryPRF and PRP are not automatically standardised or interchangeable.
Open PRF and Autologous Platelet Concentrates03Hair-specific injection
Hair Mesotherapy
Hair mesotherapy is considered specifically in the context of hair loss and scalp care, with the product and ingredients made explicit.
Decision boundaryHair and aesthetic mesotherapy are not merged into one claim.
Open Hair Mesotherapy04Autologous tissue approach
Autologous Microtransplantation
A small autologous tissue sample is mechanically prepared for a clearly recorded clinical purpose.
Decision boundaryTissue source, processing, sterility and evidence limits require explanation.
Open Autologous MicrotransplantationClinical Methods · 05—08
Tissue · product source · regulatory setting
A method name is not enough for tissue-based approaches.
Harvest, processing, product source and regulatory status determine what can reasonably be compared.
05Tissue-based approach
Stromal Vascular Fraction (SVF)
SVF is considered according to the harvest method, processing route and intended clinical purpose.
Decision boundaryMechanical and enzymatic processing have different regulatory implications.
Open Stromal Vascular Fraction (SVF)06Two forms · one page
Microfat and Nanofat
Microfat and nanofat share one topic but differ in tissue structure, processing and intended use.
Decision boundaryThe terms are not synonyms and do not imply regeneration.
Open Microfat and Nanofat07Product-dependent approach
Exosome-Based Approaches
Exosome-based products are reviewed by source, manufacture, quality evidence and the clinical evidence actually available.
Decision boundaryEarly data do not establish a standard product or result.
Open Exosome-Based Approaches08Polynucleotide-based approach
Polynucleotides (PN/PDRN)
PN and PDRN are distinguished by the actual product, source material and intended use.
Decision boundaryComposition and product status must be checked before consideration.
Open Polynucleotides (PN/PDRN)Clinical Methods · 09—11
Development · controlled stimulation · light
Newer and supportive routes need measurable limits.
Biological rationale, device parameters and clinical evidence remain visible; novelty is not proof of quality.
09Developing approach
Stem Cell-Based Approaches
This is a heterogeneous field with different sources, processing steps and levels of evidence.
Decision boundaryThe term stem cell does not establish quality, safety or hair regeneration.
Open Stem Cell-Based Approaches10Medical procedure
Medical Microneedling
Device, needle depth, sterility, scalp findings and any combination are planned together.
Decision boundaryMedical microneedling is not equivalent to home cosmetic use.
Open Medical Microneedling11Light-based approach
Photobiomodulation and LED Therapy
Wavelength, power, dose, interval and device class are necessary to describe photobiomodulation meaningfully.
Decision boundaryClinical and home devices cannot be compared by the word LED alone.
Open Photobiomodulation and LED TherapyEvidence and Regulation
No ranking of methods
Four checks keep marketing terms separate from a clinical recommendation.
Evidence is method-, diagnosis- and protocol-specific and cannot be transferred automatically to every product or cause of hair loss.
Clinical evidence
Study design, population, comparator, measurement method and follow-up are read together.
Product and preparation
Source material, manufacturer, concentration, processing and quality records remain part of assessment.
Regulatory status
A device, medicine, tissue process and medical procedure are not presented as the same status.
Measurable follow-up
Standardised photographs and planned review points are preferable to an immediate visual impression.
Personal Treatment Plan
No intervention can be a valid outcome
The result of assessment is a plan, not automatically a treatment.
Selection depends on clinical purpose, starting point, evidence, safety and practical follow-up over time.
One method
A single, clearly reasoned approach with a defined aim and review point.
Ordered combination
More than one measure only when each role, sequence and assessment remains identifiable.
Another direction
Medication, dermatological assessment or surgical review may take priority.
Observation
Document the course, resolve uncertainties and decide again when the basis is stronger.
Treatment and Travel
Connect Istanbul and home follow-up
A treatment in Istanbul should remain medically coherent after the return journey.
Some methods require repeated sessions or longer follow-up, so travel is considered only after the clinical plan is defined.
- 01Before
Initial orientation
History, existing findings and suitable photographs help prepare the in-person visit.
- 02In Istanbul
Medical examination
Scalp, pattern, product documentation, risks and a realistic aim are reviewed together.
- 03After assessment
Proceed or defer
Only then are treatment, combination, repetition or another direction considered.
- 04After return
Documented review
Photographic review, symptoms and criteria for continuing are agreed before travel home.
Risks, Limits and Alternatives
Safety before treatment preference
Not every starting point belongs immediately in an elective treatment plan.
Active scalp disease, rapidly changing or unexplained loss and an unfavourable benefit-risk balance require another priority first.
01Clarify first
Active or uncertain findings
Inflammation, infection, scarring or rapid change are assessed before an elective method.
02Review risk
The method may not fit
Health conditions, medicines, allergies, healing and the actual product can argue against treatment.
03Reset the aim
The expectation is not achievable
Clinical methods do not automatically create new follicles or replace diagnosis and donor planning.
Alternatives may include dermatological assessment, medication, documented observation, surgical review or no intervention.
The Doctor Aslan Approach
Medical position
The right method begins with the right boundary.
Medical responsibility means separating a product name, biological rationale and clinically supportable benefit — and advising against treatment when the basis is not sound.
Diagnosis before product
Visible hair loss is medically assessed before a product is selected.
Documentation before use
Source, preparation, device and consent remain traceable.
Review before repetition
A further session follows a defined review, not automatically.
Limits before claims
Safety and an achievable aim take priority over novelty.
Medical responsibility: Dr İsmail AslanMedical review: 24 August 2026General patient information; no personal diagnosis or outcome guarantee
Frequently Asked Questions
Short and clear
Questions commonly asked before a decision.
These answers provide general orientation and do not replace personal diagnosis or treatment planning.
01What is Clinical Hair Treatments?+
Clinical Hair Treatments is described on this page as one defined clinical route. Its role, limits and possible alternatives are considered together rather than treating the method name as a personal recommendation.
02Who may be assessed for Clinical Hair Treatments?+
Suitability depends on the medical question, history, examination, the exact product or device where relevant, realistic aims and an individual benefit–risk assessment.
03What remains undecided after an online review?+
Diagnosis, definitive suitability, the treatment protocol, product, dose or device settings, expected response and the option not to proceed remain subject to personal medical assessment.
04How are treatment and follow-up in Istanbul planned?+
The in-person examination remains the decision point. Expected early reactions, warning signs, the direct contact route, return travel and access to appropriate local medical care are discussed before treatment.
Next Step
Physician-led · no product or outcome promise